GlassScriptPhysician profile
Randolph Augustus Malone
NPI 1497726814
$3,084.54
in general payments reported to CMS, 2019-2025
24 companies · $601 in 2025
The $601 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $153 · 2021: $746 · 2022: $502 · 2023: $483 · 2024: $300 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.19 |
| Education | $123.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $676.21 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $563.37 | 2021-2025 | Dupixent |
| Genzyme Corporation | $289.66 | 2019-2025 | |
| Glaxosmithkline, LLC. | $284.99 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $168.64 | 2019-2025 | |
| Csl Behring | $147.82 | 2022-2025 | Andembry, Haegarda |
| Genentech USA, INC. | $129.85 | 2019-2025 | Xolair |
| Bayer Healthcare Pharmaceuticals INC. | $117.92 | 2024 | |
| Amgen INC. | $115.96 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $101.20 | 2020-2024 | Takhzyro, Hyqvia |
| Optinose US, INC. | $83.76 | 2019-2022 | |
| Pfizer INC. | $67.92 | 2020-2024 | |
| Ionis Pharmaceuticals, INC. | $52.12 | 2025 | |
| Kaleo, INC. | $46.21 | 2019-2022 | |
| Alk-Abello, INC | $38.25 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $34.10 | 2021 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Biocryst US Sales Co., LLC | $26.55 | 2022 | |
| Merck Sharp & Dohme LLC | $26.06 | 2019-2023 | |
| Pharming Healthcare, INC. | $22.45 | 2025 | Ruconest |
| Sunovion Pharmaceuticals INC. | $18.66 | 2019 | |
| Leo Pharma INC. | $16.20 | 2022 | |
| Grifols USA, LLC | $15.33 | 2025 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.